The FDA on May 16, 2024, granted accelerated approval to IMDELLTRA® (Tarlatamab-dlle) (Imdelltra, Amgen, Inc.) for Extensive Stage Small Cell Lung Cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA® is a product of Amgen, Inc.
Bottom Ad
Advertisement
Subscribe
